Industries
Pharma R&D Outsourcing
All research in Pharma R&D Outsourcing — 6 reports.
35/100
JOINN Laboratories (China) Co., Ltd.
JOINN Laboratories is China's largest listed non-clinical CRO, running GLP toxicology and drug-safety studies while owning a herd of more than 20,000 research primates carried on the balance sheet at fair value. Reported earnings are now driven by that biological-asset line rather than by service margins: H1 2026 guidance puts attributable net profit at RMB 600.1 million to RMB 900.2 million on revenue of only RMB 668.6 million to RMB 739.0 million, with macaque revaluation contributing RMB 703 million to RMB 777 million while laboratory services swing between a RMB 142 million loss and a RMB 65 million profit. Rating Avoid: at CNY 49.70 the A-share trades near 75x trailing earnings and at roughly a 130% premium to its own H-share, capitalizing a cyclical accounting gain as if it were durable service profit.
44/100
Hangzhou Tigermed: A Genuine China CRO Recovery, Priced Ahead of Clean Earnings
Hangzhou Tigermed is China's largest homegrown clinical CRO, running a domestic clinical-trial franchise alongside a fast-growing overseas and laboratory-services business that together produced RMB 6.83 billion of 2025 revenue. Bookings and backlog both re-accelerated in 2025 (net new bookings up 20.6%, backlog up 15.4%) and first-quarter 2026 operating cash flow rose 60.5%, yet adjusted attributable profit still fell 58.5% to RMB 355 million and the controlling shareholders have been under CSRC investigation over historical disclosure issues since May 2026. Rating Hold: the recovery in orders and cash flow is real, but at CNY 51.90 the A-share already prices much of that repair while clean earnings quality and governance credibility still need proof, leaving little margin of safety.
55/100
Pharmaron Beijing: Order Momentum Returns, but the Platform Is Still Unfinished
Pharmaron Beijing is an integrated drug R&D outsourcing platform whose laboratory-services engine, RMB 8.16 billion of FY2025 revenue at a 45.1% gross margin, still funds the build-out of CMC, clinical and biologics capacity. FY2025 revenue grew 14.8% to RMB 14.10 billion while attributable profit fell 7.2% to RMB 1.66 billion on a prior-year investment-gain base, and Q1 2026 new orders grew more than 30% with CMC orders up over 50%, yet North America supplies roughly 61.8% of revenue under a sector-wide geopolitical discount. Rating Hold: a good discovery-and-chemistry franchise is funding a real but unfinished move into broader CRDMO, leaving the current CNY 29.11 price short of a margin-of-safety entry below CNY 25.
47/100
Samsung Biologics (207940) Zen Horizon Framework Deep Dive: A Global CDMO Champion Newly Purified by Spin-Off, Where an Excellent Business Meets a Rich Price and Unproven BIOSECURE Upside
Samsung Biologics is the world's largest biologics CDMO, a contract development and manufacturing platform that became a pure-play CDMO after spinning off Samsung Bioepis in November 2025. Its core case rests on world-leading capacity of roughly 780,000 liters, operating margin near 45%, revenue growth above 30%, relationships with 17 of the world's top 20 pharmaceutical companies, and a $21.4B backlog, but the valuation already prices in capacity leadership and BIOSECURE upside that has not yet been proven in orders. Report rating Hold: a top-tier compounder deserves a premium, but at the current price the margin of safety is thin.
46/100
WuXi AppTec Zen Horizon Framework Deep Dive: A Fine Business, a Fair Price, and an Unresolved Geopolitical Catch
WuXi AppTec is the global leader in small-molecule CRDMO, with the highest gross margin among peers and core recurring net profit still up 32.6%. The central thesis is that the business quality remains high, but the H-share price of HKD 125.6 sits only inside a neutral valuation band, lacks a margin of safety, and still carries unresolved BIOSECURE/1260H binary geopolitical risk plus ongoing controlling-shareholder selling. Research rating Watch: a high-quality compounder worth monitoring, but current price and unresolved tail risk do not justify a new-position entry.
38/100
Charles River Laboratories Deep Value Investment Research
Charles River Laboratories is a real non-clinical R&D outsourcing platform now moving through portfolio restructuring and regulatory migration. The core thesis is that the current price of about $180.71 sits only near the lower end of neutral value ($180-195), with too little margin of safety, while an ideal entry would require a pullback to $130-150. Report Rating Watch: a credible cash-generative platform, but the recovery and regulatory transition are not yet proven enough for a Buy.